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SUMOylation is the covalent conjugation of SUMO
polypeptides to cellular target proteins. Psmd1 is a
subunit of the proteasomal 19S regulatory particle
that acts as a docking site for Adrm1, another protea-
some subunit that recruits ubiquitinated substrates
for proteolysis. Here, we show that the SUMOdecon-
jugating enzyme xSENP1 specifically interacts with
Psmd1 and that disruption of xSENP1 targeting
delays mitotic exit. Psmd1 becomes SUMOylated
through the action of the SUMO E3 enzyme PIASy.
We mapped SUMOylation sites within Psmd1 and
found that SUMOylation of a critical lysine immedi-
ately adjacent to the Adrm1-binding domain regu-
lates the association of Adrm1 with Psmd1.
Together, our findings suggest that the interaction
of Psmd1 with Adrm1 is controlled by SUMOylation
in a manner that may alter proteasome composition
and function. These findings demonstrate a mecha-
nism for regulation of ubiquitin-mediated protein
degradation by ubiquitin-like proteins of the SUMO
family.
INTRODUCTION
SUMOylation is the covalent conjugation of SUMO proteins
(small ubiquitin-related modifiers) to target proteins through the
sequential action of E1 (Uba2/Aos1) and E2 (Ubc9) enzymes
(Gareau and Lima, 2010). Most targets also require a SUMO
ligase or E3 enzyme to facilitate their SUMOylation.
SUMOylation is reversed by SUMO-specific deconjugating en-
zymes called Ulp/SENPs (Mukhopadhyay and Dasso, 2007).
Yeast has two Ulp/SENPs, Ulp1p and Ulp2p. ULP1 is essential,
and ulp1D strains arrest in mitosis (Li and Hochstrasser, 1999).
There are four Ulp1p-like Ulp/SENPs in mammals: SENP1,
SENP2, SENP3, and SENP5 (Mukhopadhyay and Dasso, 2007).
SENP1 and SENP2 are most similar to each other; like Ulp1p,
the vertebrate SENP1/SENP2 subfamily is important for mitosis
(Cubeñas-Potts et al., 2013; Era et al., 2012; Zhang et al., 2008).
Proteasomes are multisubunit proteases that mediate the
degradation of proteins that have been targeted for destruction1842 Cell Reports 7, 1842–1848, June 26, 2014 ª2014 The Authorsby ubiquitination (Tomko and Hochstrasser, 2013). Ubiquitinated
degradation substrates are fed into the proteasome’s catalytic
20S core particle (20S-CP) through the 19S regulatory particle
(19S-RP). Psmd1 (Rpn2 in yeast) is the largest subunit of 19S-
RP (Tomko and Hochstrasser, 2013). Psmd1 plays a key struc-
tural role in the 19S-RP and acts as a docking site for other
proteasome subunits, including Adrm1 (Rpn13 in yeast), a
subunit that recruits ubiquitinated substrates to the 19S-RP.
Adrm1 also recruits and activates UCH37, a deubiqitinating
enzyme (Lee et al., 2011). Proteasomal subunits have been
found in proteomic screens for SUMOylation substrates (Becker
et al., 2013; Golebiowski et al., 2009), but no role of their modifi-
cations has been reported.
Taking advantage of the fact that the frog X. laevis has only
one member of the SENP1/SENP2 subfamily, xSENP1 (Wang
et al., 2009), we have investigated the mitotic function of
SENP1/SENP2 proteases through manipulation of xSENP1 in
Xenopus egg extracts (XEEs) (Maresca and Heald, 2006). We
found that disruption of xSENP1 targeting caused defects
in mitotic exit and that xSENP1 associated strongly with
Psmd1.Wemapped SUMOylation sites within Psmd1 and found
that modification of a critical lysine adjacent to the Adrm1 bind-
ing domain regulates Adrm1’s association with Psmd1. Our
findings suggest Psmd1 SUMOylation controls proteasome
composition and function, providing a mechanism for regulation
of ubiquitin-mediated protein degradation through the SUMO
pathway.
RESULTS AND DISCUSSION
The N-terminal domains of SENPs determine their localization
and contribute to their substrate specificity (Mukhopadhyay
and Dasso, 2007). We reasoned that addition of a recombinant
N-terminal xSENP1 fragment (xSENP1N) might act in a domi-
nant-negative manner by displacing endogenous xSENP1. We
added maltose binding protein (MBP)-fused xSENP1N to
M-phase-arrested XEEs (CSF-XEEs), followed by induction of
anaphase (Figures 1A and 1B). As shown by the rate of Cyclin
B protein destruction, the addition of xSENP1N delayed
anaphase progression in comparison to control XEEs to which
MBP was added, suggesting that xSENP1 function is important
in some way for mitotic exit.
To understand xSENP1’s function, we performed pull-down
assays from XEEs (Figure 1C) and observed several proteins
Figure 1. Psmd1 Binds xSENP1 Specifically in XEEs
(A) A total of 5 mM MBP-tagged N-terminal xSENP1 fragment (mbp-xSENP1N; amino acids 1–420) or MBP was added to CSF-XEEs in the presence of sperm
chromatin. Anaphase was induced with 0.6 mM Ca2+ (time = 0 min), and samples were taken periodically for analysis by western blotting with anti-Cyclin B and
anti-MBP. Lower left panel shows silver stain of input proteins (mbp and mbp-xSENP1N).
(B) Mean Cyclin B levels from three independent experiments performed as in (A), quantified using ImageJ. Error bars represent SD.
(C) Pull-down (PD) samples from XEEs using MBP, MBP-tagged full-length xSENP1 (f.l.). or MBP-xSENP1N (N) subjected to SDS-PAGE and silver staining.
Arrowheads and asterisks indicate bait and binding proteins, respectively. Proteins within the bracket were analyzed by mass spectrometry. Psmd1 association
to xSENP1 was confirmed by western blotting (lower panel). Input: 2.5%
(D) Immunoprecipitates (IP) from interphase (Int) or mitotic (Mito) XEEs using either immunoglobulin G (Mock) or xSENP1 antibodies were analyzed by western
blotting with the indicated antibodies. Input: 1%
(E) Pull-down samples from XEEs usingMBP, MBP-xSENP1, or MBP-xSENP3 were analyzed by western blotting with anti-Psmd1 (upper panel) or silver staining
(lower panel). Asterisks indicate bait. Input: 2.5%
(F) Reciprocal pull-down assays samples from XEEs using MBP or MBP-Psmd1 were analyzed by western blotting for the indicated proteins. Asterisks indicate
bait. Input: 5%on silver-stained gels that bound xSENP1 and xSENP1N, but not
MBP. These proteins were excised from a Coomassie-blue-
stained gel (bracket) and analyzed by mass spectrometry.
Psmd1 was among the most prominent proteins identified, and
western blotting confirmed its association to both full-length
xSENP1 and xSENP1N (Figure 1C, bottom panel). Psmd1 was
present in anti-xSENP1 immunoprecipitates from interphase
and mitotic XEEs (Figure 1D), indicating that this association
occurred throughout the cell cycle.
We examined Psmd1 binding to other SENPs in two ways.
First, we performed pull-down experiments comparing MBP-
xSENP1 to MBP-xSENP3, the other Ulp1p-like SENP present
in XEEs (Wang et al., 2009) (Figure 1E). While Psmd1 bound
strongly to MBP-xSENP1, its binding to MBP-xSENP3 was
negligible. Second, we performed reciprocal pull-down experi-
ments using MBP-Psmd1, which showed a strong interaction
with xSENP1, but not xSENP3, xSENP6, or xSENP7 (Figure 1F).
Additionally, we observed coprecipitation of bacterially ex-
pressed Psmd1 with purified xSENP1, indicating that they asso-
ciate in the absence of any other XEE components (Figure S1).
Together, our data suggest that Psmd1 binds xSENP1 in a
direct, specific fashion.C
Western blotting of isolated mitotic spindles formed in CSF-
XEEs indicated that both xSENP1 and Psmd1 are concentrated
on spindles (Figure S2A). A smaller amount of these proteins
associated with chromosomes purified from nocodazole-treated
CSF-XEEs. We determined the distribution of Psmd1 and
xSENP1 on mitotic chromosomes by immunofluorescent stain-
ing. Psmd1 and xSENP1 concentrated at centromeres (Fig-
ure S2B). SUMOylated species are abundantly concentrated
on mitotic centromeres in XEEs (Ryu and Azuma, 2010), and
we speculated that Psmd1 might be a SUMOylation target. To
test this idea, MBP-Psmd1 was incubated in XEEs, reisolated,
and analyzed by western blotting. Antibodies against MBP and
SUMO2 both detected a smear migrating more slowly than
MBP-Psmd1 that was abolished in reactions containing a domi-
nant-negative form of the SUMO E2 enzyme (dnUbc9) (Fig-
ure S2C and Figure 2A). No corresponding smear was observed
when we blotted the same samples with SUMO1 antibodies.
These data suggest that Psmd1 is a paralog-specific target for
conjugation to SUMO2/3 in mitotic XEEs.
PIASy, a major mitotic SUMO E3 ligase in XEEs (Azuma et al.,
2005), was among the proteins that were pulled down from XEEs
with Psmd1 (Figure 2A). However, we did not detect RanBP2,ell Reports 7, 1842–1848, June 26, 2014 ª2014 The Authors 1843
Figure 2. Psmd1 Is Modified by SUMO2/3 in
XEEs and In Vitro
(A) MBP or MBP-Psmd1 were incubated under the
indicated conditions and pulled down using
Amylose resin. Where indicated, dominant-
negative E2 (dnUbc9) was included to inhibit
SUMOylation. The samples were analyzed by
western blotting with antibodies against the indi-
cated proteins. Silver stain shows bait proteins.
Input: 5%
(B) T7-tagged Psmd1 or T7-tagged TopoIIaCTD
were subjected to in vitro SUMOylation with or
without PIASy and analyzed by western blotting
with T7 antibodies. 1 and 2 indicate SUMO1 and
SUMO2, respectively. Asterisks and arrows indi-
cate SUMO-conjugated species and PIASy,
respectively.
(C) Immunoprecipitations (IP) from XEEs using
immunoglobulin G and Psmd4 antibodies were
subjected to in vitro reactions as in (B), except that
SUMO3 replaced the other paralogs. GG indicates
that the mature form of SUMO3 was used, while G
indicates use of a truncated, nonconjugatable
form. Recombinant (Rec.) Psmd1 was concurrently subjected to in vitro SUMOylation. The samples were analyzed by western blotting, as indicated.
Antibodies against subunit C2 were used to detect 20S proteasome. Input: 5%
(D) Sperm chromatin was incubated for 60 min in XEE in the absence or presence of GST-SUMO2 and PIASy. The isolated chromosome fractions (Chr.) were
processed and pulled down for GST-SUMO2 (see Experimental Procedures), followed by western blotting with the indicated antibodies. Asterisks indicate
SUMO-modified forms of Psmd1. pH3 indicates phosphohistone H3. Input: 6%another SUMO ligase reported to associate with Psmd1 (Yi et al.,
2007). PIASy binding to Psmd1 was enhanced upon dnUbc9
addition. This phenomenon may be analogous to ‘‘substrate
trapping,’’ wherein dominant-negative mutant enzymes form
stabilized complexes with their substrates (Flint et al., 1997).
We tested whether PIASy catalyzed Psmd1 SUMOylation within
in vitro assays that also contained E1 and E2 at concentrations
similar to those in XEEs. We observed PIASy-dependent
Psmd1 SUMOylation (Figure 2B), which occurred specifically
with SUMO2, as we had observed in XEEs. Moreover, PIASy
SUMOylated Psmd1 in the context of the intact 19S-RP; we
immunoprecipitated proteasomes from XEE using Psmd4 anti-
bodies and subjected them to in vitro SUMOylation as in Fig-
ure 2B. The efficiency of Psmd1 SUMOylation within the
19S-RP was comparable to that observed for recombinant
Psmd1 (Figure 2C).
To determine whether chromosome-associated Psmd1 be-
comes SUMOylated, we isolated chromosomes formed in
CSF-XEEs containing sperm chromatin in the presence or
absence of exogenous PIASy and glutathione S-transferase
(GST)-SUMO2. GST-SUMO2-conjugated proteins were isolated
from the chromosomal fractions by affinity chromatography, and
we found that a portion of Psmd1 was SUMOylated in themitotic
chromosomal fraction (Figure 2D). Together, our data indicated
that Psmd1 is a substrate for PIASy-dependent conjugation to
SUMO2/3 and that it can become SUMOylated in the context
of intact proteasomes and on mitotic chromosomes.
We wished to determine the sites of Psmd1 SUMOylation and
the consequences of this modification. A SUMOylation site pre-
diction program, SUMOsp 2.0, indicated that potential SUMO
acceptor lysines lie mainly within the Psmd1 C-terminal domain.
Human Adrm1 associates to the proteasome through the C ter-1844 Cell Reports 7, 1842–1848, June 26, 2014 ª2014 The Authorsminus of Psmd1 (He et al., 2012);XenopusAdrm1 likewise bound
the C terminus of Psmd1 (Figure S3), while xSENP1 bound to the
middle domain of Psmd1 (PC domain, amino acids 348–782).We
hypothesized that Psmd1 SUMOylation might alter Adrm1 bind-
ing. To test this idea, we SUMOylated Psmd1 in vitro using
elevated concentrations of enzymes to enhance its modification.
Psmd1was isolated on beads, whichwere introduced to XEEs to
allowAdrm1 binding. After reisolation andwashing, SUMOylated
Psmd1 beads showed correspondingly less coprecipitating
Adrm1 than those from a mock reaction lacking ATP (Figure 3A),
indicating that SUMOylation compromises Psmd1 binding to
Adrm1.
We prepared a Psmd1 C-terminal fragment (Psmd1C; amino
acids 783–951) that harbors most of the predicted SUMO
acceptor lysines and the Adrm1-binding motif. Psmd1C was
incubated with SUMO2, E1, E2, and PIASy in the presence or
absence of ATP (Figure S4). We incubated SUMOylated or
mock-treated Psmd1C with XEEs, followed by isolation and
detection of Adrm1 by western blotting. Adrm1 binding was
lost in close correlation with increasing levels of Psmd1C
SUMOylation (Figure 3B). We predicted that if SUMOylation
occludes Adrm1 binding to the C terminus of Psmd1, its
deSUMOylation should restore binding. To test this idea, a
deSUMOylation step was included in the SUMOylation-coupled
pull-down (Figure 3C). As before, Psmd1C SUMOylation
decreased Adrm1 binding (Figure 3D, conditions 1 and 2), but
the deconjugation of SUMOylated Psmd1C by an exogenous
xSENP1 catalytic fragment restored Adrm1 interaction (condi-
tions 2, 3, and 4), indicating that SUMOylation indeed blocks
Adrm1’s association to the C-terminal domain of Psmd1.
We used liquid chromatography-tandem mass spectrometry
to map acceptor lysines of in-vitro-SUMOylated full-length
Figure 3. SUMOylation of the Psmd1 C Terminus Negatively Regu-
lates its Interaction with Adrm1
(A) Full-length MBP-Psmd1 was either mock-treated (lane 2) or subjected to
in vitro SUMOylation (lane 3), followed by incubation with XEEs. The samples
were subjected to affinity chromatography, followed by western blotting of the
bound fractions with anti-Psmd1 (upper panel; bracket indicates SUMOylated
Psmd1) or anti-Adrm1 (lower panel). Input: 5% of mock-treated input reaction.
(B) A T7-tagged C-terminal fragment of Psmd1 (Psmd1C) was subjected to
in vitro SUMOylation for 0 (lane 2), 20 (lane 3), and 60 min (lane 4). The beads
were incubated in CSF-XEEs, reisolated, and washed. Bound proteins were
analyzed by western blotting with anti-Adrm1 (upper panel) or anti-T7 (lower
panel). Lane 1 shows a control sample with empty beads. The amounts
unSUMOylated T7-Psmd1C (below lower panel) and of Adrm1 bound to the
beads (above upper panel) were quantitated for reactions containing T7-
Psmd1C and normalized relative to levels in lane 2. Input: 10%
(C) Schematic of experiment Figure 3D. In vitro SUMOylation reactions of T7-
Psmd1C containing one volume (13) or three volumes (33) were incubated
without or with ATP, respectively, followed by proportional addition of CSF-
XEEs and further incubation for 30 min at 23C. T7-Psmd1C-bound proteins
were isolated from the first reaction (ATP) on beads. The latter (33) was split
into three equal portions; T7-Psmd1C-bound proteins were isolated on beads
from the first portion without further manipulation. The second and third
portions were supplemented with buffer or xSENP1 catalytic domain, respec-
tively, and incubated for 30 min at 23C, followed by capture of T7-Psmd1C-
bound proteins on beads. All samples were eluted with 13 sample buffer.
(D) Proteins prepared as in (C) were analyzed by western blotting with anti-
Adrm1 and anti-T7. Buf., buffer. Input: 5%Psmd1 and Psmd1C, in combination with a candidate approach.
We identified nine lysines near the Adrm1-binding motif as bona
fide SUMO acceptors (amino acids 848, 849, 853, 861, 862, 865,
866, 867, and 932 of Xenopus Psmd1; Figures 4A and 4B).
A Psmd1C mutant in which these lysines were substituted
with arginine, Psmd1C-K9R, showed dramatically reduced
SUMOylation (compare lanes 2 and 10). Psmd1C-K9R showed
modest SUMOylation at elevated SUMO enzyme concentra-
tions, although it remained below the level of SUMOylation
observed for wild-type Psmd1C (lanes 3 and 11). One predicted
SUMOylation site, K932, lies immediately adjacent to the Adrm1-C
binding site and has an excellent ‘‘JKXE/D’’ SUMOylation
consensus motif (Yang et al., 2006) (Figure 4A). Mutation of
K932 caused a substantial reduction of SUMOylation (Figure 4B,
lanes 2 and 6), although other lysines were still modified at high
enzyme concentrations (lanes 3 and 7). Notably, PIASy was
essential for efficient SUMOylation of Psmd1C (Figure 4B, lanes
4, 8, and 12).
We subjected Psmd1C wild-type (WT), K932R, and K9R to
in vitro SUMOylation or mock treatment, followed by their intro-
duction to XEEs to analyze Adrm1 binding as in Figure 3A. The
capacity of WT Psmd1C to bind Adrm1 decreased by 85% after
SUMOylation (Figures 4C and 4D). However, SUMOylation of
either mutant protein caused a less than 10% decrease in
Adrm1 binding in comparison to the mock-treated control sam-
ples. Taken together, our results suggest that K932 is a major
SUMO acceptor whose conjugation regulates Adrm1 binding,
while SUMOylation of nearby lysines may help to modulate
Adrm1 recruitment.
Collectively, our data suggest a model in which Psmd1 be-
comes SUMO2/3-modified by PIASy, preventing Adrm1 docking
(Figure 4E). We propose that xSENP1 removes SUMOylation
from Psmd1, allowing Adrm1 loading and the degradation of
key proteasomal targets. Under circumstances when xSENP1
is inhibited, this pathway would be disrupted, causing an inability
to degrade Adrm1-dependent substrates. While our data indi-
cate that PIASy and xSENP1 mediate Psmd1 SUMOylation
and deSUMOylation, respectively, precisely how and when their
activities are regulated remain to be elucidated. We do not know
the identity of the protein(s) whose degradation might be
controlled in this manner, although clearly this will be another
important point for future investigation. Notably, Psmd1 associ-
ates with xSENP1 throughout the cell cycle (Figure 1D), so this
mechanism could operate in other contexts.
Disruption of xSENP1 targeting in XEEs delays mitotic exit
(Figures 1A and 1B). SENP1 depletion from cultured mammalian
cells likewise delays sister chromatid segregation and anaphase
onset (Cubeñas-Potts et al., 2013), suggesting that SENP1 func-
tion is conserved among vertebrates. However, the bulk of
Psmd1 remains un-SUMOylated in XEEs (Figure 2). Thus, only
a small fraction of proteasomes should be inhibited through
Psmd1 SUMOylation, making it difficult to rationalize how such
a marginal loss of proteasomal activity could slow mitotic pro-
gression. These issues might be reconciled in two ways. First,
deSUMOylation of a protein other than Psmd1 could be neces-
sary, and the delay caused by xSENP1N might reflect failure to
deSUMOylate this substrate. Alternatively, there might be a
SUMO-regulated proteasome subpopulation that is essential
for the proteolysis of key proteins. For example, if ubiquitination
of mitotic targets were both spatially regulated and closely
coupled to degradation, local regulation of proteasomes could
also modulate their destruction. This is an attractive idea, partic-
ularly because activation of the anaphase-promoting complex, a
major mitotic ubiquitin ligase, is coupled to chromosome locali-
zation (Sivakumar et al., 2014), where we likewise observe
SUMOylated Psmd1 (Figure S2). Further work will clearly be
needed to test these possibilities.
There are a number of ways in which Psmd1 SUMOylation





Figure 4. SUMOylation on Lys 932 of Psmd1 Is Critical to Inhibit Adrm1 Binding
(A) C-terminal sequences of human, mouse, chicken, frog, fish, and yeast Psmd1 protein, aligned using ClustalW2 program. The green box indicates Adrm1-
binding motif. Lysines identified as SUMO acceptors in X. laevis are in red and bold. The black box shows a SUMOylation consensus motif. Note that SUMO
acceptor lysines are conserved among higher eukaryotes.
(B) Psmd1C wild-type (WT), K932R, and K9R were subjected to in vitro reactions that contain various concentrations of SUMO E1, E2, and PIASy. Small ‘‘+’’
reactions contain enzyme concentrations similar to XEE endogenous levels: 15 nM E1, 30 nM E2, and 10 nM PIASy. Medium ‘‘+’’ reactions contain double the
level of SUMO enzymes. Bold ‘‘+’’ reactions contain 150 nM E1 and 300 nME2, but not PIASy. Note that PIASy is essential for Psmd1C SUMOylation. The double
dot indicates alternatively SUMOylated forms. The single dot indicates residually SUMOylated forms of Psmd1C observed after nine lysines were mutated to
arginine.
(C) Psmd1CWT and mutants treated as in (B), under conditions without (lanes 1, 5, and 9) or with SUMOylation (lanes 3, 7, 11), were used for pull-down assays in
XEEs. Bound proteins were analyzed by western blotting with anti-Adrm1 and anti-Psmd1. Input: 5%
(D) Two independent experiments performed as in (C) were quantified using ImageJ. The graph shows Adrm1 levels bound to SUMOylated Psmd1C WT or
mutants normalized to Adrm1 bound to the same forms of Psmd1 without prior SUMOylation. Error bar shows SD.
(E) Model: PIASy conjugates SUMO2/3 (Su) to the C terminus of Psmd1 (extension from 19S-RP), occluding the Adrm1 (Ad) docking site. Active xSENP1 (S1*)
antagonizes this modification, allowing Adrm1 recruitment. The balance of conjugation and deconjugation might be regulated, perhaps through conversion of
xSENP1 between inactive (S1) and active forms, with deconjugation favoring proteasome activity. Ub, ubiquitinated targets of Adrm1.in Psmd1-Adrm1 interactions could modulate the recruitment of
ubiquitinated proteins to the 19S-RP. Proteasomes bind ubiqui-
tinated substrates through Adrm1 and Rpn10 (Tomko and Hoch-
strasser, 2013), which show distinct substrate recognition
profiles. Genetic analysis shows that these two recognition path-
ways are not functionally redundant (Elangovan et al., 2010;
Fatimababy et al., 2010), and some substrates are particularly1846 Cell Reports 7, 1842–1848, June 26, 2014 ª2014 The Authorsdependent upon Adrm1 for their degradation, including Cyclin
B (Chen et al., 2010). Additionally, Adrm1 mediates the recruit-
ment and activation of UCH37, an enzyme that antagonizes
the degradation of some ubiquitinated species (Lee et al.,
2011). Changes in Adrm1 binding are thus strongly predicted
to modulate the stability of these proteins. Finally, association
to the 19S-RP places xSENP1 in an ideal location to cleave
SUMO chains from proteins that are targeted for proteasomal
degradation by SUMO-targeted ubiquitin ligases (STUbLs)
(Geoffroy and Hay, 2009) and thus to modulate the destruction
of STUbL substrates.
In summary, SUMO conjugation and deconjugation of Psmd1
by PIASy and xSENP1 provides a mechanism for regulating pro-
teasomal composition as well as an important point of crosstalk
between ubiquitin-like modifier pathways.
EXPERIMENTAL PROCEDURES
XEE Preparation
Metaphase XEEs (CSF-XEEs) and sperm chromatin were prepared as
described previously (Azuma, 2009). Interphase XEEs were prepared by the
addition of 0.6 mM CaCl2 to CSF-XEEs and incubation for 60 min at 23
C.
Unless otherwise specified, sperm chromatin was added at a concentration
of 1,000 nuclei per ml of final reaction. All procedures involving frogs were
approved by the NICHD Animal Care and Use Committee (ASP-12-025).
Pull-Down Assays and Immunoprecipitation
For pull-down assays, bacterially expressed His6-tagged proteins were bound
to Talon affinity resin (Clontech), and MBP-tagged proteins were bound to
Amylose resin (Biolabs) overnight at 4C. The saturated resins were blocked
with 5% gelatin before mixing with 1:10 diluted XEEs. The resins were incu-
bated between 30 min and 2 hr at 23C, washed three times with 13 PBS
with 0.1% Tween 20 (PBS-T), and eluted in 13 SDS sample buffer. For immu-
noprecipitations (Figure 1D), xSENP1antibodieswere bound toprotein A-Dyna
beads (Invitrogen) overnight at 4C and crosslinked using dimethylpimelimi-
date 2 HCl (Thermo Scientific). The antibody-linked beads were incubated in
1:10 diluted XEE, washed with 13 PBS-T, and eluted in 13 SDS sample buffer.
In Figure 2D, chromosomes were formed in CSF-XEEs plus 8,000 sperm nuclei
per ml, with or without PIASy (50 nM) and GST-SUMO2 (5 mM). The isolated
chromosome pellet was sonicated on ice and incubated for 30min with DNase
I (Sigma) at 4C. The samples were centrifuged at 10,000 3 g for 10 min, and
the supernatants were subjected to GST-SUMO2 affinity chromatography
over glutathione Sepharose. After elution with 13 SDS sample buffer, the sam-
ples were resolved on 4%–12% or 4%–20% tris-glycine gradient SDS-PAGE
gels (NOVEX). Unless otherwise indicated, the input lane of each pull-down
experiment using XEEswas loadedwith a volume of XEE equivalent to the indi-
cated percentage of the total reaction volume.
In Vitro SUMOylation Assays
Unless otherwise specified, in vitro SUMOylation assayswere performed in the
presence of 15 nM E1, 30 nM E2, 10 nM PIASy, 5 mM SUMO paralogs, 0.5 mM
substrates, and 2.5 mM ATP. The reaction buffer contained 5 mM MgCl2,
100–120mMNaCl, 20mMHEPES (pH 7.8), 5% glycerol, and 0.05% Tween20.
Reactions were incubated in 27C for 1 hr and stopped with 13 SDS sample
buffer. For in vitro SUMOylation-coupled pull-down assays (Figures 3 and 4,
exclusive of Figure 3B), 10 mg MBP-tagged Psmd1C was incubated with
150 nM E1, 300 nM E2, 100 nM PIASy, and 10 mM SUMO2GG at 27C for
2 hr, with or without 5 mM ATP. The reactions were diluted 10-fold and incu-
bated with Amylose resin for 90 min. The beads were added to CSF-XEEs
that had been diluted 10-fold with CSF-XB buffer and incubated for 30 min
at 23C to allow Adrm1 binding. Finally, the beads were collected, washed
three times with 13 PBS-T and eluted in 13 SDS sample buffer. Where indi-
cated, xSENP1 catalytic domain (amino acids 300–618) was added at a final
concentration of 50–100 nM.
For the in vitro SUMOylation-coupled pull-down assay (Figure 3B), S-tagged
Psmd1C was expressed in E. coli (BL21DE3Star) cultures containing 5% glyc-
erol and 3% ethanol at 16C for 40 hr and purified using nickel nitrilotriacetic
acid beads followed by Superdex 200HR and Mono Q columns. A total of
2 mg of S-tagged Psmd1C was incubated at 27C for 0, 10, 20, or 60 min in
a reaction buffer B (40 mM Tris, 100 mM NaCl, 0.05% Tween-20, 5% glycerol,
2 mM dithiothreitol, 4 mM MgCl2, 2 mM ATP) that contained 150 nM E1,
200 nM E2, 50 nM PIASy, and 10 mM SUMO2GG. The reaction was dilutedC
20-fold with buffer B containing 10 mM EDTA and incubated with S-protein
resin (EMD Millipore) for 90 min at 4C. The beads were then mixed with
CSF-XEEs that had been diluted 10-fold in CSF-XB buffer containing
10 ng/ml SUMO2-vinyl sulfone (Mukhopadhyay et al., 2006) to block SUMO
isopeptidases and incubated for 90 min at 4C. The beads were retrieved by
centrifugation at 400 3 g for 10 s, washed three times in CSF-XB buffer con-
taining 0.05% Tween-20, and eluted in 13 SDS sample buffer.
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